ClinicalTrials.gg
Not yet recruitingNCT07694297CONTROL-ACLFUpdated Jul 9, 2026

Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure

A Phase 2 interventional study of NTZ 500mg BID on top of SOC in Acute Decompensation of Liver Cirrhosis and Established Acute-on-Chronic Liver Failure, sponsored by Genfit. Not yet recruiting. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Genfit · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 74 Years
Sex
All
01

Study summary

Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients with Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure

02

Conditions studied

  • Acute Decompensation of Liver Cirrhosis
  • Established Acute-on-Chronic Liver Failure

Keywords

  • bis in die twice a day, BID
  • Nitazoxanide, NTZ
  • Standard of Care, SOC
  • Acute-on-Chronic Liver Failure, ACLF
  • Acute Decompensation, AD
03

In context

Acute-On-Chronic Liver Failure

167 studies on the registry are indexed under Acute-On-Chronic Liver Failure; 61 are open to participants now.

This study's planned enrollment of 16 is below the median of 73 across 96 interventional studies indexed under Acute-On-Chronic Liver Failure.

Browse Acute-On-Chronic Liver Failure studies →

Lead sponsor

Genfit is the lead sponsor of 23 studies on the registry; 2 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Participants with liver cirrhosis of any underlying etiology (liver cirrhosis diagnosed by standard clinical criteria, imaging findings, and/or histology)
  • Recent acute clinical deterioration within 10 days prior to Day 1 defined as the onset of ascites, HE, gastrointestinal bleeding, or any combination of them with or without infection with or without organ failure
  • Adult male or female participants, defined as having reached the legal age of majority according to local regulations, aged \<75 years on the day of signing form (ICF)
  • Participants or legal representative willing and able to provide written informed consent in accordance with local ethical and legal requirements
  • Participants able to swallow peroral medication

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  1. Known to nitazoxanide or any known of the IMP
  2. Nitazoxanide use within 30 days prior to SCR
  3. Uncontrolled acute bleeding at SCR or Day 1
  4. Participants with poorly controlled seizure disorder
  5. Severe circulatory failure requiring the use of high dose vasopressors (eg, dopamine >15 μg/kg/min, or epinephrine >0.1 μg/kg/min, or norepinephrine >0.1 μg/kg/min); the use of terlipressin or low dose norepinephrine to treat hepatorenal syndrome is not an exclusion criterion
  6. Uncontrolled severe infection with hemodynamic instability or shock
  7. Need for renal replacement therapy (RRT) or any extracorporeal liver support device
  8. Any significant disease considered to be potentially detrimental or would preclude the participant from participating in and completing the study as assessed by the PI
  9. Individuals for whom the PI deems that study participation would be unsafe or not in the interest of the participant
  10. Pregnancy or lactation
  11. Participants of and non-sterile male participants who are not willing to use adequate from SCR to 90 days after the final dose of IMP
  12. Participation in another interventional clinical study within 30 days of SCR.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    NTZ 500mg BID on top of SOC

    Treatment period NTZ 500mg BID on top of SOC during 7 days.

    Drug: NTZ 500mg BID on top of SOC

Interventions

  • DrugNTZ 500mg BID on top of SOC

    Treatment period NTZ 500mg BID on top of SOC

06

What researchers measure

Primary outcomes

  1. To evaluate the safety of 500 mg BID NTZ administered perorally

    Safety defined as the incidence, relatedness, and severity (NCI-CTCAE v6.0 grade) of TEAEs including SAEs (comprising the evaluation of vital signs, ECGs, and laboratory parameters).

    Time frame: over 7 days on top of SOC follow-up period up to Day 28.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Aug 2027, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2026
First posted
Jul 9, 2026
StartEst.
Oct 2026
Primary completionEst.
Aug 2027
CompletionEst.
Dec 2027
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07694297
Lead sponsor
Genfit
Responsible party
Sponsor
First posted
Jul 9, 2026
Start date
Oct 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 9, 2026

Study contacts

Pejvack Motlagh, MD, MSc
Contact
contact@genfit.com
+333 20 16 40 00

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion